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Background: Little is known about the biological behavior of Xp11.2 translocation renal cell carcinomas (RCCs) as
few clinical studies have been performed using a large sample size.
Methods: This study included 103 consecutive young adult patients (age≤ 45 years) with RCC who underwent partial
or radical nephrectomy at our institution from 2008 to 2013. Five patients without complete clinical data were
excluded. Of the 98 remaining patients, 16 and 82 patients were included in the Xp11.2 translocation and non-Xp11.2
translocation groups, respectively. Clinicopathologic data were collected, including age, gender, tumor size, laterality,
symptoms at diagnosis, surgical procedure, pathologic stage, tumor grade, time of recurrence and death.
Results: Xp11.2 translocation RCCs were associated with higher tumor grade and pathologic stage (P < 0.05, Fisher’s
exact test). During the median follow-up of 36 months (range: 3–71 months), the number of cancer-related deaths
was 4 (4.9 %) and 3 (18.7 %) in the non-Xp11.2 translocation and Xp11.2 translocation groups, respectively. The
Kaplan-Meier cancer specific survival curves revealed a significant difference between non-Xp11.2 translocation
RCCs and Xp11.2 translocation RCCs in young adults (P = 0.042).
Conclusions: Compared with non-Xp11.2 translocation RCCs, the Xp11.2 translocation RCCs seemingly showed a
higher tumor grade and pathologic stage and have similar recurrence-free survival rates but poorer cancer-specific
survival rates in young adults.
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Renal cell carcinoma (RCC) is the most common type of
kidney cancer in adults and accounts for approximately
3 % of adult malignancies and 90–95 % of neoplasms
arising from the kidney [1]. The morbidity and mortality
of RCC is still growing. RCC can be histologically classi-
fied into several subtypes, among which clear cell RCC
is the most prevalent and represents 70–80 % of kidney
cancers [2].
Xp11.2 translocation RCC was first listed as a specific
disease entity in the World Health Organization Classifi-
cation of Tumors in 2004 [3]. This RCC subtype is de-
fined by different translocations involving chromosome
Xp11.2, all of which result in transcription factor E3* Correspondence: gwd@nju.edu.cn; doctorghq@gmail.com
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creativecommons.org/publicdomain/zero/1.0/(TFE3) gene fusions. Several fusions of the TFE3 gene
with different genes have been identified to date, including
ASPL(17q25), PRCC(1q21), PSF(1q34), NonO(Xq12) and
CLTC(17q23) [4]. Another subset of RCC is associated
with transcription factor EB (TFEB) resulting from
t(6;11)(p21;q12). PRCC-TFE3 RCCs [5] and ASPL-TFE3
RCCs [6] are the most frequent kinds of Xp11.2 transloca-
tion RCCs.
Recent reports have shown that the incidence of
Xp11.2 translocation RCC is low. Approximately one-
third of pediatric RCCs are estimated to be Xp11.2
translocation RCCs associated with TFE3 gene fusion
[7]. Several studies have recently evaluated its incidence
as 0.9 % (6/632) in adult RCCs [8], 15 % (4/26) in young
adult RCCs [9], and 54 % (7/13) in child RCCs [10].
A meta-analysis by Rao et al. [11] demonstrated that
TFE3 + pediatric RCCs were associated with a poorer
outcome and higher stage (III/IV) than TFE3-RCCs.distributed under the terms of the Creative Commons Attribution License
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with RCC had similar recurrence-free survival rates but
better cause-specific survival rates compared with older pa-
tients. In that study, Xp11.2 translocation RCCs accounted
for at least one half of the young patients with RCC who
had developed recurrence.
Until now, few clinical studies have examined the bio-
logical behavior of Xp11.2 translocation RCCs in young
adults (≤45 years). In this study, we aimed to better define
the biological behavior of Xp11.2 translocation RCCs and
to determine whether its clinical outcomes differ from
those of non-Xp11.2 translocation RCCs in young adults.
We hypothesized that Xp11.2 translocation RCCs have
poorer prognosis than non-Xp11.2 translocation RCCs
in young adults. The objectives of this study were as
follows: (1) to compare the clinicopathologic data of
Xp11.2 translocation RCCs with that of non-Xp11.2
translocation RCCs and obtain the clinicopathologic fea-
tures that correlated with Xp11.2 translocation RCCs,
and (2) confirm if cancer-specific survival (CSS) and
recurrence-specific survival (RFS) of Xp11.2 transloca-




Of the 879 consecutive adult RCCs in our institution
from 2008 to 2013, 103 patients were in the age range of
18–45 years. Five cases without complete clinical data
were excluded. Of the remaining 98 patients, there were
16 with Xp11.2 translocation RCCs, 61 with clear cell
RCCs, 10 with papillary RCCs, 9 with chromophobe
RCCs and 2 with unclassified RCCs. In this study, we
defined young age as ≤ 45 years according to definitions
used in previous studies [9, 12]. We diagnosed Xp11.2
translocation RCCs with positive fluorescence in situ
hybridization (FISH) after initial screening according to
medical history, age, pathologic morphology and subse-
quent TFE3 immunostaining. The study was approved
by the Committee on Medical Ethics of Nanjing Drum
Tower Hospital, Jiangsu, China. All patients provided
written informed consent.
Immunostaining
To investigate the incidence of Xp11.2 translocation
RCC, TFE3 immunostaining was performed on paraffin-
embedded tissue with the primary antibody TFE3
(Millipore, Billerica MA, US) using the manual over-
night incubation methodology (using heat-induced epi-
tope retrieval and the Dako Envision detection system).
FISH
A dual-color break-apart FISH assay for TFE3 gene re-
arrangement at the Xp11.2 region was performed on theTFE3 positively stained tissue using a self-designed poly-
clonal break-apart probe. In brief, FISH of interphase
nuclei was performed on 4-μm-thick paraffin-embedded
sections. The telomere sides of TFE3 gene cloning frag-
ments (CTD-2516D6, CTD-2522 M13, and RP11-416B14)
were labeled with fluorescein-12-dUTP and the centro-
meric sides of TFE3 gene cloning fragments (CTD-2312C1,
CTD-2248C21, and RP11-959H17) were labeled with
tetramethylrhodamine-5-dUTP. After sample prepar-
ation, hybridization with labeled DNA was performed
overnight. Slides were counterstained with 4, 6-diamidino-
2-phenylindole (DAPI, Vysis, Abbott Park, IL, USA) and
analyzed using an Olympus BX-51 fluorescence microscope
(Center Valley, PA, USA). Co-localization of red and green
signals in tumor nuclei was considered negative, and a split
signal in more than 10 % tumor nuclei was regarded posi-
tive for TFE3 rearrangement.
Assessment
The collected clinicopathologic data were as follows:
age, gender, tumor size, laterality, symptoms at diagno-
sis, surgical procedure, pathologic stage, and tumor
grade. All patients presented with tumor-free status after
nephrectomy because no surgery was conservative or
cytoreductive.
All patients had undergone a thorough medical history
interview, physical examination, radiographic staging ac-
cording to the computed tomography and/or magnetic
resonance imaging of the abdomen as well as chest radi-
ography. If warranted by the patient symptoms or phys-
ical examination findings, bone scans and brain imaging
were performed.
The characteristics of the 98 patients are summarized
in Table 1. The patients were followed up every 3–12
months with imaging studies. At each consultation, the
patient’s status (alive or dead) and the degree of tumor
progression were determined. In the present study, the
endpoints of follow-up were CSS and RFS.
Statistical analysis
The intergroup differences in the categorical and con-
tinuous variables were analyzed using Fisher’s exact test
and Student’s t test, respectively. The CSS and RFS
curves were obtained for Xp11.2 translocation and non-
Xp11.2 translocation groups using the Kaplan-Meier
method and compared using a log-rank test. All statis-
tical analyses were performed using SPSS, version 17. In
all analyses, calculated P values of < 0.05 were consid-
ered to indicate significance.
Results
Patients’ outcome and pathologic results are shown in
Table 1. The Xp11.2 translocation RCCs were significantly
associated with higher tumor grade and pathologic stage







Media(Range) 40 (18–45) 27 (21–40)
Gender(n) 0.086
Male 56 (68.3 %) 7 (43.8 %)
Female 25 (31.7 %) 9 (56.3 %)
Size(cm) 0.588
Media(Range) 4.6 (1.8–17.0) 4.5 (3.0–11.5)
Laterality(n) 1.000
Left 39 (47.6 %) 7 (43.8 %)
Right 43 (52.4 %) 9 (56.3 %)
Symptoms(n)
Asymptomatic 57 (69.5 %) 11 (68.8 %)
Symptomatic 25 (30.5 %) 5 (31.3 %) 1.000
Nephrectomy (n) 0.156
Radical 49 (59.8 %) 13 (81.3 %)
Partial 33 (40.2 %) 3 (18.8 %)
Overall stage(n) 0.026
I 57 (69.5 %) 10 (62.5 %)
II 22 (26.8 %) 2 (12.5 %)
III 2 (2.4 %) 3 (18.8 %)
IV 1 (1.2 %) 1 (6.3 %)
TNM(2010AJCC)
T(n) 0.026
T1 57 (69.5 %) 10 (62.5 %)
T2 22 (26.8 %) 2 (12.5 %)
T3 2 (2.4 %) 3 (18.8 %)
T4 1 (1.2 %) 1 (6.3 %)
N(n) 0.013
N0 81 (98.8 %) 13 (81.3 %)
N1 1 (1.2 %) 3 (18.8 %)
M(n)
M0 82 (100 %) 16 (100 %)
M1 0 (0) 0 (0)
Tumor grade (n) 0.011
Low 25 (30.5 %) 0 (0 %)
Medium 38 (46.3 %) 9 (56.3 %)
High 19 (23.2 %) 7 (43.8 %)
Follow-up (mo) 0.464
Media(Range) 33.5 (7–71) 29 (3–70)
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difference was observed in age, gender, tumor size, lateral-
ity, symptoms at diagnosis, or surgical procedure.The number of cancer-related deaths was 4 (4.9 %)
and 3 (18.7 %) in the non-Xp11.2 translocation and
Xp11.2 translocation groups, respectively. Analyses of
CSS curves indicated that Xp11.2 translocation RCCs
were significantly more frequently associated with a
poorer outcome than non-Xp11.2 translocation RCCs
(P = 0.042, Fig. 1a).
A total of 12 (14.6 %) and 3 patients (18.7 %) in non-
Xp11.2 translocation and Xp11.2 translocation groups
developed recurrence, respectively. The Kaplan-Meier
RFS curves revealed no difference between these two
groups (P = 0.505, Fig. 1b).
Discussion
Xp11.2 translocation RCC has been recognized as a dis-
tinct entity in the World Health Organization renal
tumor classification scheme for 11 years. Its diagnosis is
usually based on microscopic appearance and TFE3
immunostaining. Further diagnostic testing is difficult
because fresh tissue collection for cytogenetics and mo-
lecular analysis is not routinely performed in adult
RCCs. Polymerase chain reaction can also be used to
confirm a specific gene translocation on formalin-fixed,
paraffin-embedded tissue, but it is infrequently used as a
clinical diagnostic tool and is more often used in the re-
search setting. At present, the TFE3 break-apart FISH
assay has been used to further confirm diagnosis of
Xp11.2 translocation RCC [13–16].
The incidence of Xp11.2 translocation RCC is low.
Previous studies have revealed an incidence of 0.9 (6/
632) [8] to 5 %(6/121) [17] in all adult RCCs and 15 %
(4/26) in young adult RCCs [9]. According to age at the
time of surgery, the incidence values of TFE3 positivity
in the age ranges of 0–10, 11–20, 21–30, and 31–40
years were 67 (2/3), 75 (3/4), 29 (2/7), and 14 % (6/44),
respectively (P < 0.001) [18]. Because RCC is more com-
monly encountered in the adult population, the amount of
Xp11.2 translocation RCCs in adults may exceed that in the
pediatric group. Our study revealed an incidence of 1.8 %
(16/879) in all adult RCCs and 15.5 % (16/103) in young
adult RCCs, which was consistent with previous reports.
Currently little is known concerning the biological be-
havior of Xp11.2 translocation RCCs because few clinical
studies have been performed with a large sample size.
Based on the available data, the pediatric Xp11.2 trans-
location RCC is relatively inert, and its prognosis is bet-
ter than that of adult Xp11.2 translocation RCC [19, 20].
Song et al. [21] reported that pediatric Xp11.2 transloca-
tion RCC easily invaded regional lymph nodes and was
highly malignant. However, patients with N +M0 main-
tained a favorable prognosis following surgery alone.
Xp11.2 translocation RCCs that occur in adults may be
more aggressive than those in children. Argani et al. [22]
investigated 28 adult patients with Xp11.2 translocation
Fig. 1 Cancer-specific survival (a) and recurrence-specific survival (b) analyses were computed comparing non-Xp11.2 translocation renal cell carcinomas
(RCCs) with Xp11.2 translocation RCCs in young adults. Red line: non-Xp11.2 translocation RCC; blue line: Xp11.2 translocation RCC
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Lymph node metastasis occurred in 11 of 13 patients who
could be evaluated. Meyer [23] examined 5 adult patients
with Xp11.2 translocation RCC, all of whom were in the
late stage of their disease with distant metastasis, rapid
disease course, and poor outcomes with an average sur-
vival of 18 months. Of the 7 adult patients with Xp11.2
translocation RCC that Komai et al. [9] investigated, 5
were classified as stages III–IV and 2 died within 1 year.
In a study by Zou et al. [24], the authors reported that 5
out of 9 Xp11.2 RCC patients presented with TNM stages
3–4, and 6 died 10 months to 7 years after their operation.
According to the review by Armah and Parwani [20], clin-
ical and pathological heterogeneity may exist between
pediatric Xp11.2 translocation RCC and adult Xp11.2
translocation RCC. Xp11.2 translocation RCCs had a high
degree of invasiveness, rapid disease course, and poor
prognosis in adolescents and adults over the age of
16 years, compared to that in children.
Xp11.2 translocation RCCs were extremely uncommon
after 45 years of age, but this is likely an underestima-
tion. Four patients reported by Arnoux [25] were older
than 45 years, including three women (53, 71, and
75 years old) and one man (86 years old). One patient
was metastatic at diagnosis. Radical nephrectomy was
first performed in all cases. TNM staging was T3aN2R0,
T3bN0R0, T2N2R0, and T3aN2R2, with a Furhman
grade of 4. Two patients progressed with metastasis 5
and 7 months after surgery, and two with lymphatic in-
vasion 2 and 9 months after nephrectomy. One patient
died during follow-up. Ellis et al. [26] confirmed that
older age or advanced stage at presentation predicted
death through multivariate analysis.
In this study, among 16 young adults with Xp11.2
translocation RCCs, 4 (25 %) were classified stage III–IV
and 7 (43.8 %) were Furman’s grade 3–4. The Kaplan-
Meier CSS curve revealed a significant difference between
non-Xp11.2 translocation and Xp11.2 translocation groups.
The results of the present study indicated that Xp11.2
translocation RCCs are associated with higher tumor grade
and pathologic stage and poorer CCS in young adults.
Based on morphological appearance, RCC is subdi-
vided into clear cell (70–80 %), papillary (10–15 %),
chromophobe (3–5 %), collecting duct (1 %), and unclas-
sified (1 %) subtypes [27]. Several studies have shown
age to influence the distribution of histological subtypes
[12, 28]. A more consistent finding across several studies
is that the proportion of tumors with chromophobe hist-
ology decreases with increasing age [12, 29, 30]. The
clinical behavior of chromophobe RCCs is less aggressive
than that of clear cell RCCs, independent of Fuhrman
grade or tumor size [31]. The change of histological sub-
types may be associated with better prognosis of non-
Xp11.2 translocation RCCs.Similar to conventional RCCs, radical nephrectomy is
recommended for Xp11.2 translocation RCCs. Nephron-
sparing surgery is an alternative with favorable outcomes
in symptomless small RCCs [32]. For the treatment of adult
metastatic Xp11.2 translocation RCCs, VEGF-targeted
agents appear to demonstrate some efficacy [33].
Our study had several limitations. The sample size was
small due to low incidence of this rare disease and the
follow-up time was relatively short. The calculation was
weak to answer the hypothesis. Thus, we should inter-
pret the CSS curve with some caution before further
follow-up is performed.
Conclusions
Our study showed that Xp11.2 translocation RCCs were
seemingly associated with higher tumor grade and patho-
logic stage in young adults. Moreover, it seemed that
Xp11.2 translocation RCCs had similar RFS rates but
poorer CSS rates than non-Xp11.2 translocation RCCs in
young adults. Our findings suggest that Xp11.2 transloca-
tion RCCs should be treated more actively and monitored
by follow up.
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